Identification of proximal SUMO-dependent interactors using SUMO-ID.

Cell Line, Tumor GTPase-Activating Proteins / metabolism HEK293 Cells Humans Promyelocytic Leukemia Protein / metabolism Protein Binding Protein Interaction Mapping / methods Protein Interaction Maps Protein Processing, Post-Translational SUMO-1 Protein / metabolism Small Ubiquitin-Related Modifier Proteins / metabolism Sumoylation Transcription Factors / metabolism Tumor Suppressor Protein p53 / metabolism Ubiquitin / metabolism

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
18 11 2021
Historique:
received: 04 01 2021
accepted: 19 10 2021
entrez: 19 11 2021
pubmed: 20 11 2021
medline: 28 12 2021
Statut: epublish

Résumé

The fast dynamics and reversibility of posttranslational modifications by the ubiquitin family pose significant challenges for research. Here we present SUMO-ID, a technology that merges proximity biotinylation by TurboID and protein-fragment complementation to find SUMO-dependent interactors of proteins of interest. We develop an optimized split-TurboID version and show SUMO interaction-dependent labelling of proteins proximal to PML and RANGAP1. SUMO-dependent interactors of PML are involved in transcription, DNA damage, stress response and SUMO modification and are highly enriched in SUMO Interacting Motifs, but may only represent a subset of the total PML proximal proteome. Likewise, SUMO-ID also allow us to identify interactors of SUMOylated SALL1, a less characterized SUMO substrate. Furthermore, using TP53 as a substrate, we identify SUMO1, SUMO2 and Ubiquitin preferential interactors. Thus, SUMO-ID is a powerful tool that allows to study the consequences of SUMO-dependent interactions, and may further unravel the complexity of the ubiquitin code.

Identifiants

DOI: 10.1038/s41467-021-26807-6 PMID: 34795231 PMC: PMC8602451
pubmed: 34795231
doi: 10.1038/s41467-021-26807-6
pii: 10.1038/s41467-021-26807-6
pmc: PMC8602451
doi:

Substances chimiques

GTPase-Activating Proteins 0
Promyelocytic Leukemia Protein 0
RANGAP1 protein, human 0
SALL1 protein, human 0
SUMO-1 Protein 0
SUMO1 protein, human 0
SUMO2 protein, human 0
Small Ubiquitin-Related Modifier Proteins 0
Transcription Factors 0
Tumor Suppressor Protein p53 0
Ubiquitin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6671

Informations de copyright

© 2021. The Author(s).

Références

Flotho, A. & Melchior, F. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 82, 357–385 (2013).
pubmed: 23746258 doi: 10.1146/annurev-biochem-061909-093311
Gareau, J. R. & Lima, C. D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861–871 (2010).
pubmed: 21102611 pmcid: 3079294 doi: 10.1038/nrm3011
Ullmann, R., Chien, C. D., Avantaggiati, M. L. & Muller, S. An acetylation switch regulates SUMO-dependent protein interaction networks. Mol. Cell 46, 759–770 (2012).
pubmed: 22578841 pmcid: 3614008 doi: 10.1016/j.molcel.2012.04.006
Vertegaal, A. C. SUMO chains: polymeric signals. Biochem. Soc. Trans. 38, 46–49 (2010).
pubmed: 20074033 doi: 10.1042/BST0380046
Aillet, F. et al. Heterologous SUMO-2/3-ubiquitin chains optimize IkappaBalpha degradation and NF-kappaB activity. PLoS One 7, e51672 (2012).
pubmed: 23284737 pmcid: 3527444 doi: 10.1371/journal.pone.0051672
Pichler, A., Fatouros, C., Lee, H. & Eisenhardt, N. SUMO conjugation - a mechanistic view. Biomol. Concepts 8, 13–36 (2017).
pubmed: 28284030 doi: 10.1515/bmc-2016-0030
Talamillo, A. et al. The role of SUMOylation during development. Biochem. Soc. Trans. 48, 463–478 (2020).
pubmed: 32311032 pmcid: 7200636 doi: 10.1042/BST20190390
Talamillo, A. et al. SUMOylation in the control of cholesterol homeostasis. Open Biol. 10, 200054 (2020).
pubmed: 32370667 pmcid: 7276529 doi: 10.1098/rsob.200054
Hendriks, I. A. et al. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat. Struct. Mol. Biol. 24, 325–336 (2017).
pubmed: 28112733 doi: 10.1038/nsmb.3366
Hendriks, I. A. & Vertegaal, A. C. A comprehensive compilation of SUMO proteomics. Nat. Rev. Mol. Cell Biol. 17, 581–595 (2016).
pubmed: 27435506 doi: 10.1038/nrm.2016.81
Kerscher, O. SUMO junction-what’s your function? New insights through SUMO-interacting motifs. EMBO Rep. 8, 550–555 (2007).
pubmed: 17545995 pmcid: 2002525 doi: 10.1038/sj.embor.7400980
Kumar, R., Gonzalez-Prieto, R., Xiao, Z., Verlaan-de Vries, M. & Vertegaal, A. C. O. The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. Nat. Commun. 8, 1809 (2017).
pubmed: 29180619 pmcid: 5703878 doi: 10.1038/s41467-017-01900-x
Sriramachandran, A. M. et al. Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain. Nat. Commun. 10, 3678 (2019).
pubmed: 31417085 pmcid: 6695498 doi: 10.1038/s41467-019-11549-3
Werner, A., Flotho, A. & Melchior, F. The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol. Cell 46, 287–298 (2012).
pubmed: 22464730 doi: 10.1016/j.molcel.2012.02.017
Eskiw, C. H., Dellaire, G. & Bazett-Jones, D. P. Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J. Biol. Chem. 279, 9577–9585 (2004).
pubmed: 14672938 doi: 10.1074/jbc.M312580200
Wang, J. et al. Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. J. Cell Biol. 164, 515–526 (2004).
pubmed: 14970191 pmcid: 2171989 doi: 10.1083/jcb.200305142
Bernardi, R. & Pandolfi, P. P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8, 1006–1016 (2007).
pubmed: 17928811 doi: 10.1038/nrm2277
Lallemand-Breitenbach, V. & de The, H. PML nuclear bodies: from architecture to function. Curr. Opin. Cell Biol. 52, 154–161 (2018).
pubmed: 29723661 doi: 10.1016/j.ceb.2018.03.011
Jensen, K., Shiels, C. & Freemont, P. S. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20, 7223–7233 (2001).
pubmed: 11704850 doi: 10.1038/sj.onc.1204765
Zhang, X. W. et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240–243 (2010).
pubmed: 20378816 doi: 10.1126/science.1183424
Shen, T. H., Lin, H. K., Scaglioni, P. P., Yung, T. M. & Pandolfi, P. P. The Mechanisms of PML-Nuclear Body Formation. Mol. Cell 24, 805 (2006).
pubmed: 29654784 doi: 10.1016/j.molcel.2006.11.010
Tatham, M. H. et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538–546 (2008).
pubmed: 18408734 doi: 10.1038/ncb1716
Kim, D. I. & Roux, K. J. Filling the void: proximity-based labeling of proteins in living cells. Trends Cell Biol. 26, 804–817 (2016).
pubmed: 27667171 pmcid: 5077660 doi: 10.1016/j.tcb.2016.09.004
Choi-Rhee, E., Schulman, H. & Cronan, J. E. Promiscuous protein biotinylation by Escherichia coli biotin protein ligase. Protein Sci. 13, 3043–3050 (2004).
pubmed: 15459338 pmcid: 2286582 doi: 10.1110/ps.04911804
Kim, D. I. et al. Probing nuclear pore complex architecture with proximity-dependent biotinylation. Proc. Natl Acad. Sci. USA 111, E2453–E2461 (2014).
pubmed: 24927568 pmcid: 4066523 doi: 10.1073/pnas.1406459111
Roux, K. J., Kim, D. I., Raida, M. & Burke, B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J. Cell Biol. 196, 801–810 (2012).
pubmed: 22412018 pmcid: 3308701 doi: 10.1083/jcb.201112098
Coyaud, E. et al. BioID-based identification of skp cullin F-box (SCF)beta-TrCP1/2 E3 ligase substrates. Mol. Cell Proteom. 14, 1781–1795 (2015).
doi: 10.1074/mcp.M114.045658
Dho, S. E. et al. Proximity interactions of the ubiquitin ligase Mind bomb 1 reveal a role in regulation of epithelial polarity complex proteins. Sci. Rep. 9, 12471 (2019).
pubmed: 31462741 pmcid: 6713736 doi: 10.1038/s41598-019-48902-x
Branon, T. C. et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36, 880–887 (2018).
pubmed: 30125270 pmcid: 6126969 doi: 10.1038/nbt.4201
Schopp, I. M. et al. Split-BioID a conditional proteomics approach to monitor the composition of spatiotemporally defined protein complexes. Nat. Commun. 8, 15690 (2017).
pubmed: 28585547 pmcid: 5467174 doi: 10.1038/ncomms15690
Cho, K. F. et al. Split-TurboID enables contact-dependent proximity labeling in cells. Proc. Natl Acad. Sci. USA 117, 12143–12154 (2020).
pubmed: 32424107 pmcid: 7275672 doi: 10.1073/pnas.1919528117
Banaszynski, L. A., Liu, C. W. & Wandless, T. J. Characterization of the FKBP.rapamycin.FRB ternary complex. J. Am. Chem. Soc. 127, 4715–4721 (2005).
pubmed: 15796538 doi: 10.1021/ja043277y
Bekes, M. et al. The dynamics and mechanism of SUMO chain deconjugation by SUMO-specific proteases. J. Biol. Chem. 286, 10238–10247 (2011).
pubmed: 21247896 pmcid: 3060478 doi: 10.1074/jbc.M110.205153
Shen, T. H., Lin, H. K., Scaglioni, P. P., Yung, T. M. & Pandolfi, P. P. The mechanisms of PML-nuclear body formation. Mol. Cell 24, 331–339 (2006).
pubmed: 17081985 pmcid: 1978182 doi: 10.1016/j.molcel.2006.09.013
Rabellino, A. et al. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72, 2275–2284 (2012).
pubmed: 22406621 pmcid: 3342450 doi: 10.1158/0008-5472.CAN-11-3159
Zhu, J. et al. Small ubiquitin-related modifier (SUMO) binding determines substrate recognition and paralog-selective SUMO modification. J. Biol. Chem. 283, 29405–29415 (2008).
pubmed: 18708356 pmcid: 2570875 doi: 10.1074/jbc.M803632200
Li, J. et al. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid. Br. J. Haematol. 168, 904–908 (2015).
pubmed: 25284716 doi: 10.1111/bjh.13157
Yin, C. C. et al. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J. Natl Compr. Canc Netw. 13, 19–22 (2015).
pubmed: 25583766 pmcid: 5843191 doi: 10.6004/jnccn.2015.0005
Banani, S. F. et al. Compositional control of phase-separated. Cell. Bodies. Cell 166, 651–663 (2016).
pubmed: 27374333
Chung, I., Osterwald, S., Deeg, K. I. & Rippe, K. PML body meets telomere: the beginning of an ALTernate ending? Nucleus 3, 263–275 (2012).
pubmed: 22572954 pmcid: 3414403 doi: 10.4161/nucl.20326
Van Damme, E., Laukens, K., Dang, T. H. & Van Ostade, X. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J. Biol. Sci. 6, 51–67 (2010).
pubmed: 20087442 pmcid: 2808052 doi: 10.7150/ijbs.6.51
Netzer, C., Bohlander, S. K., Rieger, L., Muller, S. & Kohlhase, J. Interaction of the developmental regulator SALL1 with UBE2I and SUMO-1. Biochem. Biophys. Res. Commun. 296, 870–876 (2002).
pubmed: 12200128 doi: 10.1016/S0006-291X(02)02003-X
Pirone, L. et al. A comprehensive platform for the analysis of ubiquitin-like protein modifications using in vivo biotinylation. Sci. Rep. 7, 40756 (2017).
pubmed: 28098257 pmcid: 5241687 doi: 10.1038/srep40756
Lauberth, S. M. & Rauchman, M. A conserved 12-amino Acid motif in Sall1 recruits the nucleosome remodeling and deacetylase corepressor complex. J. Biol. Chem. 281, 23922–23931 (2006).
pubmed: 16707490 doi: 10.1074/jbc.M513461200
Watson, I. R. & Irwin, M. S. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8, 655–666 (2006).
pubmed: 16925948 pmcid: 1601941 doi: 10.1593/neo.06439
Stindt, M. H., Carter, S., Vigneron, A. M., Ryan, K. M. & Vousden, K. H. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 10, 3176–3188 (2011).
pubmed: 21900752 pmcid: 3218624 doi: 10.4161/cc.10.18.17436
Hendriks, I. A. & Vertegaal, A. C. A high-yield double-purification proteomics strategy for the identification of SUMO sites. Nat. Protoc. 11, 1630–1649 (2016).
pubmed: 27560170 doi: 10.1038/nprot.2016.082
Becker, J. et al. Detecting endogenous SUMO targets in mammalian cells and tissues. Nat. Struct. Mol. Biol. 20, 525–531 (2013).
pubmed: 23503365 doi: 10.1038/nsmb.2526
Le Boulch, M., Brossard, A., Le Dez, G., Leon, S. & Rabut, G. Sensitive detection of protein ubiquitylation using a protein fragment complementation assay. J Cell Sci. 133, jcs240093 (2020).
Sung, M. K. et al. Genome-wide bimolecular fluorescence complementation analysis of SUMO interactome in yeast. Genome Res. 23, 736–746 (2013).
pubmed: 23403034 pmcid: 3613590 doi: 10.1101/gr.148346.112
Fang, D. & Kerppola, T. K. Ubiquitin-mediated fluorescence complementation reveals that Jun ubiquitinated by Itch/AIP4 is localized to lysosomes. Proc. Natl Acad. Sci. USA 101, 14782–14787 (2004).
pubmed: 15469925 pmcid: 522008 doi: 10.1073/pnas.0404445101
Komiya, M. et al. A genetic screen to discover SUMOylated proteins in living mammalian cells. Sci. Rep. 7, 17443 (2017).
pubmed: 29234079 pmcid: 5727073 doi: 10.1038/s41598-017-17450-7
Croucher, D. R. et al. Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers. Sci. Signal 9, ra69 (2016).
pubmed: 27405979 doi: 10.1126/scisignal.aaf0793
Lin, D. Y. et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24, 341–354 (2006).
pubmed: 17081986 doi: 10.1016/j.molcel.2006.10.019
Sahin, U. et al. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins. J. Cell Biol. 204, 931–945 (2014).
pubmed: 24637324 pmcid: 3998805 doi: 10.1083/jcb.201305148
Saitoh, N. et al. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies. Exp. Cell Res. 312, 1418–1430 (2006).
pubmed: 16688858 doi: 10.1016/j.yexcr.2006.01.013
Lallemand-Breitenbach, V. et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547–555 (2008).
pubmed: 18408733 doi: 10.1038/ncb1717
Gechijian, L. N. et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat. Chem. Biol. 14, 405–412 (2018).
pubmed: 29507391 pmcid: 5866761 doi: 10.1038/s41589-018-0010-y
Li, C., Xin, H., Shi, Y. & Mu, J. Knockdown of TRIM24 suppresses growth and induces apoptosis in acute myeloid leukemia through downregulation of Wnt/GSK-3beta/beta-catenin signaling. Hum. Exp. Toxicol. 39, 1725–1736 (2020).
pubmed: 32672070 doi: 10.1177/0960327120938845
Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193, 1361–1371 (2001).
pubmed: 11413191 pmcid: 2193303 doi: 10.1084/jem.193.12.1361
Sha, Z., Blyszcz, T., Gonzalez-Prieto, R., Vertegaal, A. C. O. & Goldberg, A. L. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J. Biol. Chem. 294, 15218–15234 (2019).
pubmed: 31285264 pmcid: 6802522 doi: 10.1074/jbc.RA119.009147
Shiio, Y. & Eisenman, R. N. Histone sumoylation is associated with transcriptional repression. Proc. Natl Acad. Sci. USA 100, 13225–13230 (2003).
pubmed: 14578449 pmcid: 263760 doi: 10.1073/pnas.1735528100
Jangal, M. et al. The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor alpha target genes. Nucleic Acids Res. 42, 11339–11348 (2014).
pubmed: 25223786 pmcid: 4191390 doi: 10.1093/nar/gku791
Flack, J. E., Mieszczanek, J., Novcic, N. & Bienz, M. Wnt-dependent inactivation of the Groucho/TLE Co-repressor by the HECT E3 ubiquitin ligase Hyd/UBR5. Mol. Cell 67, 181–193 e185 (2017).
pubmed: 28689657 pmcid: 5592244 doi: 10.1016/j.molcel.2017.06.009
Yan, W. et al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics 8, 1373–1383 (2013).
pubmed: 24149323 pmcid: 3933496 doi: 10.4161/epi.26781
Sato, A. et al. Sall1, a causative gene for Townes-Brocks syndrome, enhances the canonical Wnt signaling by localizing to heterochromatin. Biochem. Biophys. Res. Commun. 319, 103–113 (2004).
pubmed: 15158448 doi: 10.1016/j.bbrc.2004.04.156
Gonzalez-Prieto, R. et al. Global non-covalent SUMO interaction networks reveal SUMO-dependent stabilization of the non-homologous end joining complex. Cell Rep. 34, 108691 (2021).
pubmed: 33503430 doi: 10.1016/j.celrep.2021.108691
Schellenberg, M. J. et al. ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links. Science 357, 1412–1416 (2017).
pubmed: 28912134 pmcid: 5623066 doi: 10.1126/science.aam6468
Banks, D. et al. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle 5, 1719–1729 (2006).
pubmed: 16861890 doi: 10.4161/cc.5.15.3150
Wu, C. et al. The RNF20/40 complex regulates p53-dependent gene transcription and mRNA splicing. J. Mol. Cell Biol. 12, 113–124 (2020).
pubmed: 31152661 doi: 10.1093/jmcb/mjz045
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016).
pubmed: 26780180 pmcid: 4744125 doi: 10.1038/nbt.3437
Costes, S. V. et al. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 86, 3993–4003 (2004).
pubmed: 15189895 pmcid: 1304300 doi: 10.1529/biophysj.103.038422
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
pubmed: 19029910 doi: 10.1038/nbt.1511
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
pubmed: 27348712 doi: 10.1038/nmeth.3901
Snel, B., Lehmann, G., Bork, P. & Huynen, M. A. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 28, 3442–3444 (2000).
pubmed: 10982861 pmcid: 110752 doi: 10.1093/nar/28.18.3442
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Bader, G. D. & Hogue, C. W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinforma. 4, 2 (2003).
doi: 10.1186/1471-2105-4-2
Reimand, J. et al. g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 44, W83–W89 (2016).
pubmed: 27098042 pmcid: 4987867 doi: 10.1093/nar/gkw199
Sun, H. & Hunter, T. Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search. J. Biol. Chem. 287, 42071–42083 (2012).
pubmed: 23086935 pmcid: 3516753 doi: 10.1074/jbc.M112.410985
Weaver, L. H., Kwon, K., Beckett, D. & Matthews, B. W. Corepressor-induced organization and assembly of the biotin repressor: a model for allosteric activation of a transcriptional regulator. Proc. Natl Acad. Sci. USA 98, 6045–6050 (2001).
pubmed: 11353844 pmcid: 33419 doi: 10.1073/pnas.111128198
Vizcaino, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44, 11033 (2016).
pubmed: 27683222 pmcid: 5159556 doi: 10.1093/nar/gkw880
Sehnal, D. et al. Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res. 49 (W1):W431–W437 (2021).

Auteurs

Orhi Barroso-Gomila (O)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
ORCID: 0000-0002-1472-032X

Fredrik Trulsson (F)

Cell and Chemical Biology, Leiden University Medical Center (LUMC), 2333 ZA, Leiden, The Netherlands.

Veronica Muratore (V)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.

Iñigo Canosa (I)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.

Laura Merino-Cacho (L)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
ORCID: 0000-0003-1551-4074

Ana Rosa Cortazar (AR)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Coralia Pérez (C)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
ORCID: 0000-0002-1195-2563

Mikel Azkargorta (M)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
CIBERehd, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.
ProteoRed-ISCIII, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Ibon Iloro (I)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
CIBERehd, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.
ProteoRed-ISCIII, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Arkaitz Carracedo (A)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
CIBERONC, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.
Ikerbasque, Basque Foundation for Science, 48011, Bilbao, Spain.
Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), E-48940, Leioa, Spain.
ORCID: 0000-0001-5957-1260

Ana M Aransay (AM)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
CIBERehd, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.
ORCID: 0000-0002-8271-612X

Felix Elortza (F)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain.
CIBERehd, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.
ProteoRed-ISCIII, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.
ORCID: 0000-0001-8839-5438

Ugo Mayor (U)

Ikerbasque, Basque Foundation for Science, 48011, Bilbao, Spain.
Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), E-48940, Leioa, Spain.
ORCID: 0000-0003-2812-8287

Alfred C O Vertegaal (ACO)

Cell and Chemical Biology, Leiden University Medical Center (LUMC), 2333 ZA, Leiden, The Netherlands.

Rosa Barrio (R)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain. rbarrio@cicbiogune.es.
ORCID: 0000-0002-9663-0669

James D Sutherland (JD)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801 A, 48160, Derio, Spain. jsutherland@cicbiogune.es.
ORCID: 0000-0003-3229-793X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Régulateurs des protéines G › Protéines d'activation de la GTPase › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines à motif tripartite › Protéine de la leucémie promyélocytaire › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Cartographie d'interactions entre protéines › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Métabolisme › Voies et réseaux métaboliques › Cartes d'interactions protéiques › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Modification traductionnelle des protéines › Maturation post-traductionnelle des protéines › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Ubiquitines › Petites protéines modificatrices apparentées à l'ubiquitine › Protéine SUMO-1 › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Ubiquitines › Petites protéines modificatrices apparentées à l'ubiquitine › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Modification traductionnelle des protéines › Maturation post-traductionnelle des protéines › Ubiquitination › Sumoylation › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › Identification of proximal SUMO-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Ubiquitines › Ubiquitine › Identification of proximal SUMO-dependent...